Deep phenotyping of an international series of patients with late-onset dysferlinopathy.
LGMDR2
dysferlin
late onset
muscle pathology
myopathy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
17
02
2021
received:
19
11
2020
accepted:
10
03
2021
pubmed:
15
3
2021
medline:
13
8
2021
entrez:
14
3
2021
Statut:
ppublish
Résumé
To describe the clinical, pathological, and molecular characteristics of late-onset (LO) dysferlinopathy patients. Retrospective series of patients with LO dysferlinopathy, defined by an age at onset of symptoms ≥30 years, from neuromuscular centers in France and the International Clinical Outcome Study for dysferlinopathy (COS). Patients with early-onset (EO) dysferlinopathy (<30 years) were randomly selected from the COS study as a control group, and the North Star Assessment for Dysferlinopathy (NSAD) and Activity Limitation (ACTIVLIM) scores were used to assess functionality. Muscle biopsies obtained from 11 LO and 11 EO patients were revisited. Forty-eight patients with LO dysferlinopathy were included (28 females). Median age at onset of symptoms was 37 (range 30-57) years and most patients showed a limb-girdle (n = 26) or distal (n = 10) phenotype. However, compared with EO dysferlinopathy patients (n = 48), LO patients more frequently showed atypical phenotypes (7 vs. 1; p = 0.014), including camptocormia, lower creatine kinase levels (2855 vs. 4394 U/L; p = 0.01), and higher NSAD (p = 0.008) and ACTIVLIM scores (p = 0.016). Loss of ambulation in LO patients tended to occur later (23 ± 4.4 years after disease onset vs. 16.3 ± 6.8 years; p = 0.064). Muscle biopsy of LO patients more frequently showed an atypical pattern (unspecific myopathic changes) as well as significantly less necrosis regeneration and inflammation. Although LO patients more frequently showed missense variants (39.8% vs. 23.9%; p = 0.021), no differences in dysferlin protein expression were found on Western blot. Late-onset dysferlinopathy patients show a higher frequency of atypical presentations, are less severely affected, and show milder dystrophic changes in muscle biopsy.
Sections du résumé
BACKGROUND
To describe the clinical, pathological, and molecular characteristics of late-onset (LO) dysferlinopathy patients.
METHODS
Retrospective series of patients with LO dysferlinopathy, defined by an age at onset of symptoms ≥30 years, from neuromuscular centers in France and the International Clinical Outcome Study for dysferlinopathy (COS). Patients with early-onset (EO) dysferlinopathy (<30 years) were randomly selected from the COS study as a control group, and the North Star Assessment for Dysferlinopathy (NSAD) and Activity Limitation (ACTIVLIM) scores were used to assess functionality. Muscle biopsies obtained from 11 LO and 11 EO patients were revisited.
RESULTS
Forty-eight patients with LO dysferlinopathy were included (28 females). Median age at onset of symptoms was 37 (range 30-57) years and most patients showed a limb-girdle (n = 26) or distal (n = 10) phenotype. However, compared with EO dysferlinopathy patients (n = 48), LO patients more frequently showed atypical phenotypes (7 vs. 1; p = 0.014), including camptocormia, lower creatine kinase levels (2855 vs. 4394 U/L; p = 0.01), and higher NSAD (p = 0.008) and ACTIVLIM scores (p = 0.016). Loss of ambulation in LO patients tended to occur later (23 ± 4.4 years after disease onset vs. 16.3 ± 6.8 years; p = 0.064). Muscle biopsy of LO patients more frequently showed an atypical pattern (unspecific myopathic changes) as well as significantly less necrosis regeneration and inflammation. Although LO patients more frequently showed missense variants (39.8% vs. 23.9%; p = 0.021), no differences in dysferlin protein expression were found on Western blot.
CONCLUSIONS
Late-onset dysferlinopathy patients show a higher frequency of atypical presentations, are less severely affected, and show milder dystrophic changes in muscle biopsy.
Substances chimiques
Membrane Proteins
0
Muscle Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2092-2102Informations de copyright
© 2021 European Academy of Neurology.
Références
Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998;20(1):31-36. https://doi.org/10.1038/1682
Bashir R, Britton S, Strachan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet. 1998;20(1):37-42. https://doi.org/10.1038/1689
Britton S, Freeman T, Vafiadaki E, et al. The third human FER-1-like protein is highly similar to dysferlin. Genomics. 2000;68(3):313-321. https://doi.org/10.1006/geno.2000.6290
Huang Y, Laval SH, Remoortere A, et al. AHNAK a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J. 2007;21(3):732-742. https://doi.org/10.1096/fj.06-6628com
Cárdenas AM, González-Jamett AM, Cea LA, Bevilacqua JA, Caviedes P. Dysferlin function in skeletal muscle: possible pathological mechanisms and therapeutical targets in dysferlinopathies. Exp Neurol. 2016;283(Pt A):246-254. https://doi.org/10.1016/j.expneurol.2016.06.026
Bulankina AV, Thoms S. Functions of vertebrate ferlins. Cells. 2020;9(3):534. https://doi.org/10.3390/cells9030534
Urtizberea J, Bassez G, Leturcq F, Nguyen K, Krahn M, Levy N. Dysferlinopathies. Neurol India. 2008;56(3):289-297. https://doi.org/10.4103/0028-3886.43447
Harris E, Bladen CL, Mayhew A, et al. The clinical outcome study for dysferlinopathy an international multicenter study. Neurol Genet. 2016;2(4):e89. https://doi.org/10.1212/NXG.0000000000000089
Illa I, Serrano-Munuera C, Gallardo E, et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol. 2001;49(1):130-134. https://doi.org/10.1002/1531-8249(200101)49:1<130:AID-ANA22>3.0.CO;2-0
Nguyen K, Bassez G, Krahn M, et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol. 2007;64(8):1176-1182. https://doi.org/10.1001/archneur.64.8.1176
Aoki M, Liu J, Richard I, et al. Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology. 2001;57(2):271-278. https://doi.org/10.1212/WNL.57.2.271
Krahn M, Béroud C, Labelle V, et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat. 2009;30(2):E345-E375. https://doi.org/10.1002/humu.20910
Fanin M, Angelini C. Progress and challenges in diagnosis of dysferlinopathy. Muscle Nerve. 2016;54(5):821-835. https://doi.org/10.1002/mus.25367
Angelini C, Grisold W, Nigro V. Diagnosis by protein analysis of dysferlinopathy in two patients mistaken as polymyositis. Acta Myol. 2011;30:185-187.
Katz JS, Rando TA, Barohn RJ, et al. Late-onset distal muscular dystrophy affecting the posterior calves. Muscle Nerve. 2003;28(4):443-448. https://doi.org/10.1002/mus.10458
Griger Z, Nagy-Vincze M, Bodoki L, Gherardi RK, Dankó K, Hortobágyi T. Late onset dysferlinopathy mimicking treatment resistant polymyositis. Jt Bone Spine. 2016;83(3):355-356. https://doi.org/10.1016/j.jbspin.2015.03.017
Li F, Yin G, Xie Q, Shi G. Late-onset dysferlinopathy presented as “liver enzyme” abnormalities. JCR J Clin Rheumatol. 2014;20(5):275-277. https://doi.org/10.1097/RHU.0000000000000126
Klinge L, Dean AF, Kress W, et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord. 2008;18(4):288-290. https://doi.org/10.1016/j.nmd.2008.01.004
Suzuki N, Aoki M, Takahashi T, et al. Novel dysferlin mutations and characteristic muscle atrophy in late-onset Miyoshi myopathy. Muscle Nerve. 2004;29(5):721-723. https://doi.org/10.1002/mus.20025
Udd B, Stenzel W, Oldfors A, et al. 1st ENMC European meeting: The EURO-NMD Pathology Working Froup Recommended Standards for Muscle Pathology Amsterdam, The Netherlands, 7 December 2018. Neuromuscul Disord. 2019;29(6):483-485. https://doi.org/10.1016/j.nmd.2019.03.002
Gallardo E, de Luna N, Diaz-Manera J, et al. Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy. PLoS ONE. 2011;6(12):e29061. https://doi.org/10.1371/journal.pone.0029061
Diaz-Manera J, Fernandez-Torron R, Llauger J, et al. Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. J Neurol Neurosurg Psychiatry. 2018;89(10):1071-1081. https://doi.org/10.1136/jnnp-2017-317488
Seror P, Krahn M, Laforet P, Leturcq F, Maisonobe T. Complete fatty degeneration of lumbar erector spinae muscles caused by a primary dysferlinopathy. Muscle Nerve. 2008;37(3):410-414. https://doi.org/10.1002/mus.20910
Nagashima T, Chuma T, Mano Y, et al. Dysferlinopathy associated with rigid spine syndrome. Neuropathology. 2004;24(4):341-346. https://doi.org/10.1111/j.1440-1789.2004.00573.x
Ali F, Matsumoto JY, Hassan A. Camptocormia: etiology, diagnosis, and treatment response. Neurol Clin Pract. 2018;8(3):240-248. https://doi.org/10.1212/CPJ.0000000000000453
Ghosh PS, Milone M. Camptocormia as presenting manifestation of a spectrum of myopathic disorders. Muscle Nerve. 2015;52(6):1008-1012. https://doi.org/10.1002/mus.24689
Laroche M, Cintas P. Bent spine syndrome (camptocormia): a retrospective study of 63 patients. Jt Bone Spine. 2010;77(6):593-596. https://doi.org/10.1016/j.jbspin.2010.05.012
Moore U, Jacobs M, James MK, et al. Assessment of disease progression in dysferlinopathy: a 1-year cohort study. Neurology. 2019;92(5):E461-E474. https://doi.org/10.1212/WNL.0000000000006858
Mahjneh I, Marconi G, Bushby K, Anderson LVB, Tolvanen-Mahjneh H, Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord. 2001;11(1):20-26. https://doi.org/10.1016/S0960-8966(00)00157-7
Cohen TV, Cohen JE, Partridge TA. Myogenesis in dysferlin-deficient myoblasts is inhibited by an intrinsic inflammatory response. Neuromuscul Disord. 2012;22(7):648-658. https://doi.org/10.1016/j.nmd.2012.03.002
Dillingham BC, Benny Klimek ME, Gernapudi R, et al. Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice. J Neurol Sci. 2015;356(1-2):157-162. https://doi.org/10.1016/j.jns.2015.06.042
Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med. 1988;318(21):1363-1368. https://doi.org/10.1056/NEJM198805263182104
Alonso-Pérez J, González-Quereda L, Bello L, et al. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain. 2020;143(9):2696-2708. https://doi.org/10.1093/brain/awaa228
Takahashi T, Aoki M, Suzuki N, et al. Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B. J Neurol Neurosurg Psychiatry. 2013;84(4):433-439. https://doi.org/10.1136/jnnp-2011-301339
Izumi R, Takahashi T, Suzuki N, et al. The genetic profile of dysferlinopathy in a cohort of 209 cases: genotype-phenotype relationship and a hotspot on the inner DysF domain. Hum Mutat. 2020;41(9):1540-1554. https://doi.org/10.1002/humu.24036
Park HJ, Bin HY, Hong J, et al. Null variants in DYSF result in earlier symptom onset. Clin Genet. 2020;99:396-406. https://doi.org/10.1111/cge.13887
Cagliani R, Magri F, Toscano A, et al. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat. 2005;26(3):283. https://doi.org/10.1002/humu.9364
Hogarth MW, Defour A, Lazarski C, et al. Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B. Nat Commun. 2019;10(1):2430. https://doi.org/10.1038/s41467-019-10438-z
Defour A, Medikayala S, Van der Meulen JH, et al. Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. Hum Mol Genet. 2017;26(11):1979-1991. https://doi.org/10.1093/hmg/ddx065
Witting N, Andersen LK, Vissing J. Axial myopathy: an overlooked feature of muscle diseases. Brain. 2016;139(1):13-22. https://doi.org/10.1093/brain/awv332